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The expansionof apolyglutamine tract in theubiquitously expressedhuntingtinprotein causesHuntington’s disease (HD), a dominantly
inherited neurodegenerative disease.We show that the activity of the cholesterol biosynthetic pathway is altered inHD. In particular, the
transcription of key genes of the cholesterol biosynthetic pathway is severely affected in vivo in brain tissue fromHDmice and in human
postmortem striatal and cortical tissue; thismolecular dysfunction is biologically relevant because cholesterol biosynthesis is reduced in
cultured humanHD cells, and total cholesterolmass is significantly decreased in the CNS of HDmice and in brain-derived ST14A cells in
which the expression of mutant huntingtin has been turned on. The transcription of the genes of the cholesterol biosynthetic pathway is
regulated via the activity of sterol regulatory element-binding proteins (SREBPs), andwe found an50% reduction in the amount of the
active nuclear form of SREBP inHD cells andmouse brain tissue. As a consequence,mutant huntingtin reduces the transactivation of an
SRE–luciferase construct even under conditions of SREBP overexpression or in the presence of an exogenous N-terminal active form of
SREBP. Finally, the addition of exogenous cholesterol to striatal neurons expressing mutant huntingtin prevents their death in a dose-
dependent manner. We conclude that the cholesterol biosynthetic pathway is impaired in HD cells, mice, and human subjects, and that
the search for HD therapies should also consider cholesterol levels as both a potential target and disease biomarker.
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Introduction
Huntington’s disease (HD) is a progressive, autosomal domi-
nant, neurodegenerative disorder characterized bymotor, cogni-
tive, and behavioral dysfunctions. Themutation leading to HD is
an expansion of a CAG repeat close to the 5 end of the HD gene
(TheHuntington’s Disease Collaborative Research Group, 1993)
that leads to an expanded glutamine tract in huntingtin, a 348
kDa protein with individual neuroprotective activities (Riga-
monti et al., 2000; Cattaneo et al., 2001; Zuccato et al., 2001).
Although huntingtin is ubiquitously expressed, the brain is pri-
marily affected in HD, with the striatal medium spiny neurons
and cortical neurons being particularly vulnerable (Reiner et al.,
1988). The underlying mechanism in HD is attributable to the
increased toxicity of the mutant protein. In addition, there is
evidence indicating that some disease phenotypes may be attrib-
utable to the loss of normal huntingtin prosurvival activities
(Cattaneo et al., 2001).
The aim of this study was to test the hypothesis of a dysfunc-
tion in cholesterol biosynthesis in HD. Cholesterol is synthesized
locally in the brain (Jurevics and Morell, 1995), in which it con-
stitutes a major component of myelin. During development, the
demand for cholesterol in the brain is particularly high, and cho-
lesterol/sphingolipid depletion leads to a gradual loss of synapses
and spines (Thiele et al., 2000; Hering et al., 2003). Cholesterol is
also crucially involved in optimal neurotransmitter release
(Mauch et al., 2001). In adult brain, the available cholesterol
seems to derive from basal biosynthesis, mainly by astrocytes
(Barres and Smith, 2001; Pfrieger, 2003a), and its accumulation
during the early phases of life. Although little is known about the
role of cholesterol in this tissue district, defects in cholesterol
homeostasis have been linked to neurodegenerative diseases such
as Niemann-Pick type C and Alzheimer’s disease (Mahley and
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Huang, 1999; Battaile and Steiner, 2000; Dietschy and Turley,
2001), and our previous microchip studies of a cell model of HD
(Sipione et al., 2002) showed decreased transcription of the genes
encoding for the enzymes of the cholesterol biosynthetic
pathway.
We show here that the cholesterol biosynthetic pathway is
altered in HD cells and mouse and human brain. This dysfunc-
tion is attributable to amutant huntingtin-dependent decrease in
the amount of the active form of SREBP transcription factor
translocating to the nucleus and a subsequent reduction in the
transcription of key genes of cholesterol biosynthesis, a decrease
in the end product (i.e., cholesterol level) and a smaller total
cholesterol mass. We also found that the addition of exogenous
cholesterol to striatal neurons expressingmutant huntingtin pre-
vents their death in a dose-dependent manner.
Materials andMethods
Radioactive semiquantitative reverse transcription-PCR analyses. Total
RNA was isolated from the tissues and cells using TRIZOL reagent (In-
vitrogen, Carlsbad, CA) and reverse-transcribed into single-stranded
cDNA using Superscript II RNase H Reverse Transcriptase (Invitro-
gen) as described by the manufacturer. Radioactive PCR was performed
in a total volume of 50 l containing cDNA, consisting of 0.25 g of
RNA, 20 mM Tris-HCl, pH 8.4, 50 mM KCl, 1.5 mM MgCl2, 0.2 mM
dNTPs, 1.7 Ci of [ 32P]dCTP, 0.4 M of each primer, and 2 U of Taq
polymerase (Invitrogen). All of the genes were amplified using multiple
cycle numbers (20–25 cycles) to determine the appropriate conditions
for obtaining semiquantitative differences in their expression. The cycle
steps andprimer sequences are available on request. ThePCRproductswere
separated by means of nondenaturing 6% PAGE and visualized by
autoradiography.
Cell cultures. The human primary fibroblasts and huntingtin-
inducible cells were cultured in 5%CO2 at, respectively, 37°C and 33°C in
DMEM, supplemented as described previously (Rigamonti et al., 2000;
Sipione et al., 2002), unless otherwise specified. Only one control fibro-
blast cell line was used, because, as reported previously (Corsini et al.,
1991), cholesterol biosynthetic pathway parameters are well character-
ized and similar in multiple fibroblast cell lines. We tested 10 other con-
trol lines in the past, and the individual experiments have shown the
same production of de novo cholesterol after lipoprotein-deprived serum
(LPDS) exposure. The well characterized fibroblast control cell line,
namely PF inCorsini et al. (1991), was used. FibroblastHD cell lines were
obtained according to standard procedures from symptomatic Italian
HD patients and were provided by Prof. S. Di Donato (Carlo Besta Neu-
rological Institute) and by Prof. M. Racchi (University of Pavia). LPDS
was prepared as described previously (Corsini et al., 1986) and was used
in the experiments evaluating cholesterol biosynthesis. Lipid-deprived
serum was prepared as described previously (Hannah et al., 2001).
Evaluation of cholesterol biosynthesis in HD cells. Cultured human fi-
broblasts were incubated under normal growth conditions (with me-
dium plus 10% FCS) or lipid-deprived conditions (medium plus 10%
LPDS) on Barloword Scientific (Stone, UK) cell culture-treated plates.
Cholesterol synthesis was measured by incorporating radioactive acetate
into cellular sterols (Brown et al., 1978; Corsini et al., 1987) (supplemen-
tal material, available at www.jneurosci.org). Triplicate samples of each
cell clone were tested in two independent experiments.
Measurement of total cholesterol in tissues and cells. To measure total
cholesterol levels in tissue, the animals were perfused with saline, their
brains were dissected, and the striatum and cortex were isolated. The
lipid fraction was isolated by means of solvent extraction (supplemental
material, available at www.jneurosci.org), and total cholesterol was as-
sayed using the Cholesterol kit (Clonital, Lombardia, Italy) according to
the instructions of the manufacturer and normalized by tissue weight
and protein concentration, which was assayed using a BCA protein assay
kit (Pierce, Rockford, IL). An adapted procedure was followed to evalu-
ate cholesterol concentrations in cell cultures (supplemental material,
available at www.jneurosci.org).
Preparation of membrane and nuclear extracts. The cells were plated at
70% confluence and, on day 1, doxycycline (1 g/ml) was added to
induce the expression of exogenous huntingtin. On day 2, the cells were
exposed to 5% delipidated fetal calf serum containing medium and, on
day 3, all of the cells received 25 g/ml N-acetyl-leucine-leucine-
norleucinal (Sigma, St. Louis,MO) 2 h before harvesting. Themembrane
and nuclear lysates were extracted as described in the supplemental ma-
terial (available at www.jneurosci.org).
Western blotting and immunocytochemistry. The protein concentra-
tions in the samples were measured using BCA reagent (Pierce), and
aliquots (50 g of protein) of the membrane and nuclear fractions un-
derwent, respectively, 6.5 or 10% SDS-PAGE before being transferred to
nitrocellulosemembranes. Themembraneswere saturatedwith 5%non-
fat milk and Tris-buffered saline with 1 Tween 0.1% and incubated at
room temperature for 2 h with anti-SREBP1 mouse monoclonal anti-
body 2A4 (1:200; Santa Cruz Biotechnology, Santa Cruz, CA) or mouse
monoclonal anti-SREBP2 antibody 7D4 (a gift from Dr. T. F. Osborne,
University of California, Irvine, CA), followed by 1 h at room tempera-
ture with a secondary antibody againstmouse IgG labeledwith horserad-
ish peroxidase (Bio-Rad, Hercules, CA) diluted 1:3000. They were then
developed by chemiluminescence using the SuperSignal West Pico
Chemiluminescent Substrate (Pierce). Histone H1 rabbit polyclonal an-
tibody (1:200; Santa Cruz Biotechnology) or calnexin rabbit polyclonal
antibody (1:2000; Stressgen Biotechnologies, San Diego, CA) were used
as internal controls. The Mab2166 (1:5000; Chemicon, Temecula, CA)
andEM48antibodies (1:200;Chemicon)wereused todetect huntingtin and
mutant huntingtin aggregates, respectively. The endogenous SREBPs were
immunocytochemically analyzed, as described in the supplementalmaterial
(available at www.jneurosci.org).
DNA transfection and luciferase assays. The following constructs were
used: SRE-luciferase reporter construct (pSynSRE), expressing the par-
tial hamster hydroxy-methyl-glutaryl CoA (HMGCoA) synthase pro-
moter cloned upstream of the luciferase reporter gene (Dooley et al.,
1998); TK-HSV-SREBP1a, encoding herpes simplex virus (HSV)
epitope-tagged human SREBP1a driven by the HSV thymidine kinase
(TK) promoter (Sakai et al., 1996); CMV-nSREBP1, encoding the tran-
scriptionally active fragment of the human SREBP1a protein (1–460 aa)
driven by the cytomegalovirus (CMV) promoter (Sanchez et al., 1995).
Electroporation and luciferase activity were evaluated as detailed in the
supplemental material (available at www.jneurosci.org). Luciferase ac-
tivity was normalized to protein content in each sample, as measured by
a BCA Protein Assay kit (Pierce).
Assay of huntingtin-mediated cell death. This assay was established on
the basis of previous reports (Saudou et al., 1998). Primary striatal neu-
rons prepared from embryonic day 17 rats were electroporated with
cDNA plasmids encoding the 480 N-terminal amino acids of human
huntingtin containing an expanded (68) CAG repeat (Htt480.68) and a
plasmid encoding green fluorescent protein (GFP). The expression of
Htt480.68 and GFP in the electroporated cells was, respectively, con-
firmed byWestern blotting 6 d after plating using the 1HU-4C8 antibody
(Euromedex, Mundolsheim, France) and anti-GFP (clone 7.1 and 13.1;
Roche Diagnostics, Indianapolis, IN). The cells were plated onto 96-well
microplates and exposed to the test compounds or controls on the day of
plating. BDNF was added to eight wells per plate at a final concentration
of 5 ng/ml, as a positive control. Eight control wells received 0.5%
DMSO. Survival was measured six d after plating by counting the num-
ber of GFP-positive cells as an indicator of Htt480.68 transgene expres-
sion using a Trophos (Marseilles, France) Flash Cytometer and associ-
ated software. Htt480.68 induces 50% cell death on postplating day 6,
80–100% of which is antagonized by adding BDNF in the culture on
plating day 0.
Statistical analysis. The data were compared using Bonferroni’s post
hoc test and one-way ANOVA, as indicated.
Results
Microarray studies of an inducible cell model of HD showed
reduced mRNA levels for a subset of genes involved in the cho-
lesterol biosynthetic pathway (Sipione et al., 2002). We specifi-
cally tested whether mouse and human HD brain tissues are af-
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fected by analyzing three key genes of this
pathway: HMGCoA reductase (HMG-
CoAred), cytochrome P450 lanosterol 14
-demethylase (Cyp51) and 7-dehydroxy-
cholesterol reductase (7dhcred). Figure 1A
shows that the levels of mRNA for all three
were reduced by up to 62% in the striatum
and cortex of 12-week-old R6/2HD trans-
genic mice (Mangiarini et al., 1996) com-
pared with controls. A less dramatic, but
still significant decrease was also detected
at early symptomatic stages (6 weeks) in
most brain samples (Fig. 1B). The changes
inmRNA levelswere also confirmed in hu-
man postmortem striatal (Fig. 1C) and cor-
tical tissues taken from grades I and II (Fig.
1D) and fromgrades III and IV (supplemen-
tal Fig. 1, available at www.jneurosci.org as
supplemental material) HD patients.
Wild-type and mutant huntingtin are
ubiquitously expressed in the CNS and pe-
ripheral tissue (Trottier et al., 1995), and
thus, to test whether mutant huntingtin
induces similar gene expression changes in
peripheral cells, we analyzed the RNA ex-
tracted from primary fibroblasts taken
from control and HD patients. Figure 1E
shows that HD fibroblasts show a 35–45%
reduction in HMGCoAred, Cyp51, and
7dhcredmRNA levels.
Together, these data indicate that there
is a significant reduction in themRNAs for
HMGCoAred, Cyp51, and 7dhcred in HD
mice and human subjects.
To evaluate the biological relevance of
these alterations, we next analyzed the ac-
tivity of the mevalonate pathway in cul-
tured human fibroblasts from control,
heterozygous, and homozygous HD sub-
jects. It is known that control fibroblasts
exposed to complete medium produce
negligible levels of de novo synthesized
cholesterol (William and Avigan, 1972;
Brown et al., 1978), but their exposure to
LPDS containing medium led to a 15-fold
increase in cholesterol production, a well
standardized value that is also reported in
the literature (Corsini et al., 1991). Impor-
tantly, when the heterozygous and ho-
mozygous HD fibroblasts were exposed to
LPDS, the increase was, respectively, only
eightfold and fourfold (Fig. 2a). These
data suggest that HD cells are less capable
of upregulating the mevalonate pathway
in response to low levels of cholesterol.
However, as shown in Figure 2b, 25-OH-
cholesterol, a cholesterol derivative that
blocks cholesterol biosynthesis by increas-
ing cholesterol concentration in the endo-
plasmatic reticulum (ER) (Brown et al., 2002), equally repressed
the cholesterol biosynthesis induced by LPDS in control and ho-
mozygous HD fibroblasts, and the same occurred when low-
density lipoproteins were added (Fig. 2b). These data indicate
that human HD cells appropriately suppress cholesterol biosyn-
thesis in response to high levels of sterols but that their ability to
activate the pathway is severely affected.
Because these results may have been caused by excessive cho-
Figure 1. Reduced HMGCoAred, Cyp51, and 7dhcred gene transcription in mouse and human HD brain and peripheral cells. A,
B, Semiquantitative radioactive RT-PCR analyses of striatum and cortex from individual symptomatic 12-week-old (A) and early
symptomatic 6-week-old (B) R6/2 transgenicmice comparedwith themean values SDof three age-matched controls (co). The
tissue from each transgenic mouse was investigated by means of six independent RT-PCR analyses. wt, Wild type. C, Human
postmortem striatum from grade I HD (HD I). D, Human postmortem cortical tissue from grade I (HD I) and grade II (HD II) versus
control. E, Normal (FCrtl) and HD cultured human fibroblasts (FHD). Because of limitations in the available RNA, the grade I
striatumand cortex data relate to a single RT-PCR, repeated twice; the data from the grade II sampleswere obtained by repeating
the RT-PCR three times. The graphs show the quantitative analyses of HMGCoAred, Cyp51, and 7dhcred mRNA levels. The peak
densitometric area was normalized over the peak densitometric area of the-actin band. The data are expressed as percentages
of control values. *p0.05 and**p0.01 versuswild-type littermates (co) (A,B), controls (C,D), or normal cultured fibroblasts
(FCrtl) (E) (ANOVA). Error bars represent SEM.
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lesterol accumulation, wemeasured total cholesterol levels inHD
cells and tissues of HD mice. Figure 3 shows the behavior of
brain-derived inducible cells expressing mutant huntingtin
(Sipione et al., 2002) exposed to delipidated medium. The unin-
duced cells had higher total cholesterol levels, whereas exposure
to the doxycycline inducer led to the expected expression of mu-
tant huntingtin (data not shown) (Sipione et al., 2002) and a
progressive reduction in total cholesterol content after 96 and
120 h (Fig. 3). This effect was specific to the delipidated condition
and mutant huntingtin cells because there were no differences in
serum containing medium (Fig. 3, shaded line) or in wild-type
huntingtin-inducible cells (data not shown). We also measured
total cholesterol content in the striatum and cortex of 10-week-
old R6/2 HD transgenic mice and found a 32 4.8% reduction
compared with controls (supplemental Fig. 2, available at www.
jneurosci.org as supplemental material); similar results were ob-
tained in 5-week-old mice (data not shown). These data together
demonstrate that the reduced cholesterol synthesis in HD cells
is not caused by cholesterol accumulation and that the reduction
in total cholesterol levels may be a biolog-
ical consequence of altered cholesterol
biosynthesis.
In the presence of low cholesterol lev-
els, cholesterol biosynthesis is triggered by
the SREBPs (Hua et al., 1993), which are
known to translocate from the ER to the
Golgi after activation of the sterol-sensing
domain of SREBP cleavage activation pro-
tein (SCAP). In the Golgi, SREBPs are
cleaved by two proteases (S1P and S2P) to
obtain a 68 kDa NH2-terminal fragment
that enters the nucleus and activates the
transcription of SRE-controlled choles-
terogenic genes. The three known SREBP
isoforms each have a molecular mass of
120–125 kDa (Brown and Goldstein,
1997): SREBP1a and SREBP1c are derived
from a single gene, whereas SREBP2
(which has 50% identity with SREBP1) is
encoded by a different gene. SREBP1a is a
potent activator of all SREBP-responsive
genes, including those that mediate the
synthesis of cholesterol, fatty acids, and
triglycerides, but the roles of SREBP1c and
SREBP2 are more restricted (Horton et al., 2002). Moreover,
many SRE-controlled genes (including those studied by us) are
similarly modulated by both SREBP1a and SREBP2, as has been
shown bymicroarray and chromatine immunoprecipitation data
(Horton et al., 2003; Bennett et al., 2004).
To test the hypothesis of impaired SREBP activity in HD cells,
we evaluated the transactivation potential of an SRE element in
huntingtin-inducible cells before and after the expression of mu-
tant or wild-type huntingtin. After transiently transfecting
huntingtin-inducible cells with an pSynSRE, we performed a lu-
ciferase assay under basal conditions or after incubation in de-
lipidated medium 24 h after the addition of the doxycycline in-
ducer of huntingtin expression. As shown in Figure 4a, no
significant changes in SRE activity were detected when the differ-
ent cultures were grown in the presence of FCS. However, in line
with the data thus far reported, the exposure of the cells to delipi-
dated medium led to a statistically significant 48 10% decrease
in SRE activity only in the cultures expressing mutant huntingtin
(Fig. 4a). Because the activation of the SREBP1a isoform has
broader consequences on lipid metabolism (Shimomura et al.,
1997; Dooley et al., 1998), we performed a similar experiment by
cotransfecting the pSynSRE vector and a construct constitutively
expressing full-length SREBP1a (TK-HSV-SREBP1a). Figure 4b
shows a similar reduction in SRE activity in mutant huntingtin-
expressing cells, thus confirming suboptimal SRE activation in
mutant cells even when SREBP is overexpressed. Finally, when a
plasmid encoding the 68 kDa N terminus of the active form of
SREBP1a was cotransfected with pSynSRE, transactivation of the
SRE reporter gene was 24  8% lower in the cells expressing
mutant huntingtin than in those expressing wild-type huntingtin
(Fig. 4c).
To analyze whether the reduced SREBP-transactivating capa-
bility in HD was attributable to impaired translocation of active
SREBPs into the nucleus, we next evaluated the distribution of
these transcription factors in cells before and after the induction
of mutant or wild-type huntingtin (Fig. 5a). We concentrated on
SREBP1 (the available antibodies do not distinguish whether the
endogenous protein is SREBP1a or SREBP1c) because it is highly
Figure 2. Modulation of cholesterol biosynthesis in HD cells. a, The activity of the mevalonate pathway was evaluated by
incorporating radioactive ( 14C) acetate into the cellular sterols of cells exposed to medium containing 10% FCS or 10% LPDS. No
differences in cholesterol biosynthesis were observed between normal cultured fibroblasts (FCrtl) and HD fibroblasts (FHD) in
serum containing medium (dark gray columns). When the cells were exposed to LPDS (light gray columns), cholesterol biosyn-
thesis was significantly reduced in heterozygous and homozygous HD fibroblasts comparedwith control. **p 0.01 versus FCrtl
(ANOVA).b, Effect of 25-OH-cholesterol (25OHChol) and low-density lipoprotein (LDL) on cholesterol biosynthesis in FCrtl and HD
fibroblasts exposed to LPDS. The basal level of cholesterol biosynthesis was restored by the addition of 25OHChol or LDL in both
normal and HD cells. The results are normalized to protein content. Mean values SD of triplicate experiments. Error bars
represent SEM.
Figure 3. Total cholesterol (tot. chol.) content in inducible HD cells during exposure to de-
lipidated medium (delip). Total cholesterol levels remained unchanged in induced and unin-
duced cells cultured in serum containing medium [FCS,doxy (doxycycline); FCS,doxy;
shaded lines]. Exposure to delipidatedmedium progressively decreased total cholesterol in the
cells expressing mutant huntingtin (delip,doxy) compared with the same cells under unin-
duced conditions (delip,doxy). The results are normalized to protein (prot) content. Mean
values SD of triplicate experiments. **p 0.01 versusmutant huntingtin cells grown in the
absence of doxy (delip,doxy; ANOVA). Error bars represent SEM.
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expressed in cell cultures and brain
(supplemental Fig. 3, available at www.
jneurosci.org as supplemental material),
and first confirmed that the immunoreac-
tive bands corresponding to the precursor
of SREBP1 were equally present in con-
trols andHD cells andmice (supplemental
Fig. 3, available at www.jneurosci.org as
supplemental material). Subsequently, we
evaluated SREBP1 levels inmembrane (in-
active form) and nuclear preparations (ac-
tive form) made of cells exposed to delipi-
dated conditions, as described above.
Figure 5b shows that the exposure of cells
expressing wild-type huntingtin (or pa-
rental cells; data not shown) to delipidated
medium did not affect the translocation of
active SREBP1 into the nucleus, whereas
the nuclear preparations of mutant hun-
tingtin-expressing cells showed a 46% re-
duction in the amount of the 68 kDa active
formof SREBP1 (Fig. 5b). Figure 5, b and c,
also show that, under the same conditions,
SREBP1 precursor protein andmRNA lev-
els in the inducibleHDcells were similar to
controls at the same time points.
To investigate further the impairment
in SREBP1 translocation, we exposed pa-
rental cells, and cells expressing wild-type
or mutant huntingtin, to delipidated con-
ditions, and analyzed them immunocyto-
chemically and confocally 24 h after the
addition of the inducer. Under these con-
ditions, most (80  12%) of the cells
expressing wild-type huntingtin showed
the immunoreactive signal localized inside the nucleus, consis-
tent with SREBP1 translocation (Fig. 5d), and the same was ob-
served in the parental cell cultures (see graph); however, nuclear
SREBP1 could be detected in only 50 14% of the cells bearing
mutant huntingtin.
Together, this suggests that both the nuclear translocation of
SREBP1 and the activation of the SRE are compromised in HD
cells. To extend these data in vivo, we evaluated the levels of
SREBP1 in nuclear extracts of HD mouse brain. As shown in
Figure 5e, the nuclear level SREBP1 was reduced in 10-week-old
HD mice versus controls.
Because SREBP2 activity is also linked to cholesterol biosyn-
thesis (Horton et al., 2002), we evaluated nuclear SREBP2 levels
in extracts from HD and control samples and found that the
levels of active SREBP2 were also reduced in HD cells (supple-
mental Fig. 3, available at www.jneurosci.org as supplemental
material). Together, these results demonstrate that HD nuclei
have reduced levels of both SREBP1 and SREBP2.
A pathological hallmark of Huntington’s disease and other
polyglutamine diseases is the presence of inclusions or aggregates
of the expanded polyglutamine protein (Davies et al., 1997;
Scherzinger et al., 1997). The results of previous studies suggest
that polyglutamine inclusions may sequester polyglutamine-
containing transcription factors and deplete their concentration
in the nucleus, thus altering gene expression (Cha, 2000; Li and
Li, 2004), and thus, to test whether the reduced level of nuclear
SREBP in HD is attributable to its sequestration into mutant
huntingtin aggregates, we used Western blots to analyze brain
lysates from R6/2 transgenic mice and the inducible HD cell lines.
Despite the absence of detectable aggregates (Sipione et al., 2002)
(supplementalFig.5a, availableatwww.jneurosci.orgas supplemen-
tal material), the latter showed reduced nuclear SREBP levels. The
Western blots of nuclear and cytoplasmic lysates from the brain of
R6/2mice revealed the expectedmutanthuntingtinaggregates in the
stacking gel, but no immunoreactive bands were codetected using
the anti-SREBP antibody (supplemental Fig. 5b, available at www.j-
neurosci.org as supplemental material).We therefore conclude that
the reducednuclearSREBP levels in theHDsampleswereunlikely to
be because of SREBP sequestration into aggregates.
To estimate the pathogenic impact of the dysfunction and the
potential value of its rescue in HD, we investigated whether the
addition of exogenous cholesterol may be beneficial to primary
neurons undergoing cell death after the transfection of mutant
huntingtin. Primary striatal neurons were coelectroporated with
plasmids encoding the 480 N-terminal amino acids of human
huntingtin containing an expanded CAG repeat (Htt480.68) and
GFP cDNA (for the expression levels of Htt480.68 and GFP, see
supplemental Fig. 6, available at www.jneurosci.org as supple-
mental material). On the basis of the number of GFP cells
(Saudou et al., 1998), 50% of the cells expressing mutant hun-
tingtin had died after 6 d; this cell death was specifically attribut-
able to mutant huntingtin because no cell death was observed
after transfectionwith wild-type huntingtin (data not shown). As
demonstrated previously, the addition of BDNF to cultures pre-
vents mutant huntingtin-induced cell death in a dose-dependent
manner, withmaximum effect after the addition of 5 ng/ml at the
Figure 4. Impaired SRE activity in HD cells. a, The HMGCoA synthase SRE promoter construct (PSynSRE) was transfected into
parental, wild-type huntingtin (wt htt), or mutant huntingtin (mu htt) inducible cells, after which doxycycline (doxy) was added
for 24handwas followedby16hof exposure to FCS containingmediumor lipid-deprived conditions (delip). Parental cellsdoxy
were used as controls. b, The cells were cotransfected with PSynSRE and a construct encoding HSV epitope-tagged human
SREBP1a driven by the HSV TK promoter and exposed to completemedium (with FCS) or delipidated conditions. c, Cotransfection
of pSynSRE and a construct encoding the N-terminal active form of SREBP1a (CMV-SREBP1a Nt). In this experimental paradigm, 1
g/ml25-OH-cholesterol and10g/ml cholesterol (suppressed conditions)wereadded to the completemediumto suppress the
activation of endogenous SREBPs. In all of the luciferase assays, relative light units (RLU)were normalized to protein content, and
the data were expressed as the percentages of RLU per microgram of protein from the same cells in the absence of doxy, under
delipidated (a,b) or suppressed (c) conditions. Data aremean values of triplicate experiments, one ofwhich is shown. **p 0.01
versus each cell type grown in the absence of doxy (ANOVA). Error bars represent SEM.
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time of plating (Saudou et al., 1998; Zuccato et al., 2001) (Fig. 6a).
Importantly, the addition of increasing cholesterol concentra-
tions (from 0.3 to 10 M) promoted cell survival in a dose-
dependent manner and to an extent similar (although not iden-
tical) to the results obtained after BDNF. Figure 6b shows the
combined data of single replicates as ratios to the effect of BDNF.
Discussion
Cholesterol is a multifaceted molecule that acts as an essential
membrane component, a cofactor for signaling molecules, and a
precursor of steroid hormones (Pfrieger,
2003a,b). Although its role in brain is far
from understood, adult neurons depend
on cholesterol for most of their activities,
and defects in cholesterol homeostasis
have been linked with neurodegenerative
diseases. We report, for the first time, that
cholesterol biosynthesis is impaired in
cells carrying the HD mutation and that
this dysfunction is specific to mutant hun-
tingtin because inducible cells expressing
the wild-type protein behave like mock-
untransfected cells. In particular, the
levels of mRNA for the genes of the cho-
lesterogenic pathway are severely re-
duced in rodent HD cell models, HD
transgenic mice, and human postmor-
tem brain tissues. The molecular mech-
anism underlying this dysfunction is a
mutant huntingtin-dependent decrease
in the amount of active SREBP, which
translocates from the cytosolic compart-
ment to the nucleus in which, under
conditions of low cholesterol levels, it
should bind to, and activate the tran-
scription of, SRE-controlled genes. We
found reduced SREBP translocation in
vitro and in HD mouse brain tissue.
The reduced entry of SREBP into the
nucleus leads to decreased cholesterol syn-
thesis, a finding that was confirmed in fi-
broblasts from HD patients. It is known
that the intermediates of cholesterol biosyn-
thesis are critical for neurite outgrowth, syn-
aptic activity and stability. Neurite loss is an
early manifestation of various neurodegen-
erative disorders, including HD, in which
morphological abnormalities of the brain
and defects in synaptic activity have been
documented (Li et al., 2003; Levine et al.,
2004; Schulz et al., 2004).
Our data indicate that cholesterol dys-
function is linked tomutanthuntingtin, pre-
sumably because of its toxic activity. It is also
possible that themolecularnetwork control-
ling cholesterol biosynthesis is already com-
promised during development, even in the
absence of a detectable phenotype, and that
the late-onset clinical signs may determine
“compensatory” mechanisms, because gene
mutation carriers show subtle molecular
dysfunctions at presymptomatic stages, even
when they show no detectable clinical signs
(Varani et al., 2003; Rosas et al., 2003).
Importantly, cholesterol turnover is known to be very slow in
adult brain and could emphasize the late-onset HD phenotype. If
the supply of cholesterol to the adult brain is attributable to de
novo synthesis during development and is sufficient to maintain
neuronal functions in adulthood, it is likely that altered choles-
terol biosynthesis appears later than during the first phases of life.
Impaired cholesterol biosynthesis may contribute to the synaptic
activity and remodeling, therefore possibly contributing to the
neuronal dysfunction observed in HD. It has also been suggested
Figure 5. Impaired translocation of endogenous SREBP in HD models. a, b, Western blot analyses of endogenous SREBP1 in
nuclear and membrane extracts from parental, wild-type huntingtin (wt htt) (HD19), and mutant huntingtin (mu htt) (HD43)
inducible cells in the absence or presence of the inducer [1g/ml doxycycline (doxy)] in delipidated growthmedium. HD43 cells
(Q105;mutant clone) andHD19 cells (Q26; normal clone), respectively, overexpress theN-548aa fragment ofmutant orwild-type
huntingtin. a, Induction of wild-type or mutant huntingtin in the cells after 40 h exposure to doxy. b, Localization of the 125 kDa
inactive membrane form and the 68 kDa active nuclear form of SREBP1 in the absence or presence of wild-type or mutant
huntingtin, after 16 h in delipidated medium. Calnexin and histone H1 were, respectively, used as loading controls in the mem-
brane and nuclear fractions. The graphs show the quantitative densitometric analyses of the inactive and active forms of SREBP1
compared with calnexin and histone H1. The data are expressed as percentages of the wild-type or mutant cells without doxy. c,
Semiquantitative radioactive RT-PCR analysis of mRNA levels of SREBP1 in HD43 after incubation in delipidated growthmedium.
There were no differences in SREBP1mRNA levels in the absence or presence of mutant huntingtin. d, Immunocytochemistry for
SREBP1 in HD19 and HD43 clones under the same conditions as those described above. The graph shows themean percentage of
nuclear immunoreactivity over the total cell number obtainedby counting fourmicroscope fields (10magnification) from three
replicates per experiment. The parental (P) cells ( doxy) behaved like the wild-type huntingtin cells (data not shown). a–d,
*p 0.05 and ** p 0.01 versus each cell type grown in the absence of doxy (ANOVA). e, Localization of the 68 kDa-active form
of SREBP1 in nuclear preparations from HD and control mice. Histone H1 was used as the loading control for the nuclear fraction.
The graph shows the quantitative densitometric analysis of the nuclear form of SREBP1 compared with histone H1. TheWestern
blot represents one of five experiments that gave similar results. The data are expressed as percentages of controls (Co); the SD in
the graphwas obtained by including all of the experiments. **p 0.01 versus control tissues (ANOVA). Error bars represent SEM.
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that different neuronal populations and brain areas may require
different amounts of cholesterol that may make them more vul-
nerable (Pfrieger, 2003a,b).
Mutant huntingtin proteinmaymechanistically interferewith
SREBP activation at different levels: (1) during the SCAP-
mediated transport of SREBP from the ER to the Golgi; (2) dur-
ing SREBP cleavage by S1p and S2p proteases in the Golgi; or (3)
during the translocation of active SREBP into the nucleus. The
demonstration that an exogenous 68 kDa active formof SREBP is
also unable to activate the SRE fully in the presence of mutant
huntingtin supports the hypothesis that huntingtin acts down-
stream of SREBP activation, at the level of its entry into the nu-
cleus and that reduced SREBP nuclear translocation/activity may
depend on a broad modification of the systems controlling the
nucleocytoplasmic shuttling of transcription factors (Nakielny
and Dreyfuss, 1999; Ossareh-Nazari et al., 2001). Alternatively,
mutant huntingtin may affect the posttranslational modifica-
tions of SREBPs, whose SUMOylation subsequently reduces their
own transcriptional activities (Hirano et al., 2003), and increased
SUMO-1 (small ubiquitin-related modifier-1) activity has been
reported in HD (Steffan et al., 2004).
Finally, our data also show that addition of cholesterol par-
tially rescues neurons expressing mutant huntingtin from cell
death, thus indicating that treatments aimed at restoring choles-
terol levels may be beneficial in HD.
Dysfunctions such as those reported here could perhaps also
be exploited as a means of monitoring disease evolution in pe-
ripheral cells. The changes in cholesterol biosynthesis observed in
human primary HD fibroblasts imply that extraneural tissues are
also affected by themutation. The reduced cholesterol biosynthe-
sis observed in fibroblasts anticipates the possibility that choles-
terol measurement in these cells may be a good target in the
search for biomarkers in HD (Varani et al., 2003; Mayeux, 2004).
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